Boston Therapeutics files chewable metformin ANDA with FDA to treat diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, today announced that it has submitted an Abbreviated New Drug Application (ANDA) for chewable metformin with the U.S. Food and Drug Administration (FDA). The Reference Listed Drug at the FDA is Bristol-Myers Squibb's Glucophage® product ([metformin hydrochloride] Tablets).

"Metformin is one of the most widely prescribed diabetes drugs in the world and our neutral chemistry polysaccharide formulation will benefit pre-diabetic and diabetic patients" said David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics. "This new option in treatments fits into our pipeline of other diabetes therapeutics, including Ipoxyn^TM for limb ischemia and PAZ-320 for blood glucose management," said Dr. Platt.

"This filing is an important milestone in our diabetes program. Of the options available today in oral medications for Type 2 diabetes, metformin is currently the standard of care, and our new delivery format will expand usage", said Joan Sellers, Ph.D., Chief Technology Officer, Boston Therapeutics.

Source: Boston Therapeutics, Inc.